# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $7 pri...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or r...
https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...